Author

X. S. Guo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

P.-H. C. Chen· 2 shared S. Xu· 2 shared W. R. Liu· 2 shared C. A. Fierke· 1 shared G. K. Dubey· 1 shared H. E. Zhang· 1 shared Z. Z. Geng· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

P.-H. C. Chen

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phage-Assisted, Active Site-Directed Ligand Evolution with a Genetically Encoded Nε-Butyryl-ʟ-Lysine to Identify a Cellularly Potent and Selective Inhibitor for the ENL YEATS Domain as an Anti-Leukemia Agent

P.-H. C. Chen, X. S. Guo, H. E. Zhang, Z. Z. Geng, G. K. Dubey, C. A. Fierke, S. Xu, W. R. Liu

This study develops a phage-assisted ligand evolution method to identify potent ENL inhibitors, finding a pentapeptide with sub-nanomolar affinity and anti-leukemia activity.

bioRxiv · Jan 8, 2023 · PreprintBiochemistry

The Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Potential Drug Candidates to Treat Acute Myeloid Leukemia

X. S. Guo, P.-H. C. Chen, S. Xu, W. R. Liu

This study identifies compound 13 as a potent ENL inhibitor with favorable pharmacokinetic properties for treating AML with MLL-fusion mutations.

bioRxiv · Dec 7, 2022 · PreprintBiochemistry